您好, 歡迎來(lái)到化工儀器網(wǎng)! 登錄| 免費(fèi)注冊(cè)| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:BPS Bioscience Inc.>>Immunotherapy Cell Lines>> 78757CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line
參 考 價(jià) | 面議 |
產(chǎn)品型號(hào)78757
品 牌BPS Bioscience
廠商性質(zhì)生產(chǎn)商
所 在 地
更新時(shí)間:2023-11-11 15:51:39瀏覽次數(shù):274次
聯(lián)系我時(shí),請(qǐng)告知來(lái)自 化工儀器網(wǎng)GLP-1R/CRE Luc報(bào)告基因細(xì)胞系
ADCC Bioassay Effector Cell (Mouse)
ADCC Bioassay Effector Cell F Varia
ADCC Bioassay Effector Cell V Varia
ADCP Bioassay Effector Cell FcγRIIa
This cell line was generated from TCR Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by exogeneous overexpression of human CD8 (NM_001768.6) using lentiviral transduction (CD8a Lentivirus, BPS Bioscience #78648). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.
TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat cells was confirmed by genomic sequencing and by flow cytometry and expression of CD8 was confirmed by flow cytometry. The cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621).
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請(qǐng)輸入賬號(hào)
請(qǐng)輸入密碼
請(qǐng)輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購(gòu)買(mǎi)風(fēng)險(xiǎn),建議您在購(gòu)買(mǎi)產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。